[Frontiers in Liver Transplantation in Indication and Techniques]

Overview

Journal Chirurg

Specialty General Surgery

Date 2018 Nov 11

PMID 30413847

Authors

W Schoning

R Ollinger

M Schmelzle

J Pratschke

Affiliations

Soon will be listed here.

Abstract

Background: The frontiers in liver transplantation are intrinsically expansions of indications, e.g. hepatocellular carcinoma and (perihilar) cholangiocarcinoma, recipients with more severe concomitant diagnoses or "soft" contraindications and technically demanding reconstruction procedures of vascular structures (for portal vein thrombosis or aorto-hepatic conduits). In addition, an extension of the donor pool with suboptimal donor organs (old donors and steatotic livers) is of interest.

Methods: This article presents the current situation based on personal experiences in daily practice and an appropriate literature review.

Results: A significant reduction of 1‑year patient survival has been reported in Germany. The percentage of so-called marginal donor organs is inversely proportional to the very low donation rate and parallel to the waiting list mortality. Simultaneously, the proportion of inpatients with multiple organ failure is rising.

Conclusion: Results-oriented and controlled liver transplantation currently prohibits making inroads into the previously intrinsic frontiers. As long as the current circumstances do not change, a shift in the intrinsic frontiers of that which is surgically feasible will not be possible. The current situation forces the transplant surgeon to apply a more restrictive indications and organ acceptance policy. With this approach we can try to regain the previously excellent short- and long-term results of a 1‑year survival of 90% and a 20-year survival of 50%.

References

Pichlmayr , Weimann , Tusch , Schlitt . Indications and Role of Liver Transplantation for Malignant Tumors. Oncologist. 1997; 2(3):164-170. View

De Vreede I, Steers J, Burch P, Rosen C, Gunderson L, Haddock M . Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl. 2000; 6(3):309-16. DOI: 10.1053/lv.2000.6143. View

Yerdel M, Gunson B, Mirza D, Karayalcin K, Olliff S, Buckels J . Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation. 2000; 69(9):1873-81. DOI: 10.1097/00007890-200005150-00023. View

Yao F, Ferrell L, Bass N, Watson J, Bacchetti P, Venook A . Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33(6):1394-403. DOI: 10.1053/jhep.2001.24563. View

Molmenti E, Roodhouse T, Molmenti H, Jaiswal K, Jung G, Marubashi S . Thrombendvenectomy for organized portal vein thrombosis at the time of liver transplantation. Ann Surg. 2002; 235(2):292-6. PMC: 1422428. DOI: 10.1097/00000658-200202000-00019. View

Sudan D, Deroover A, Chinnakotla S, Fox I, Shaw Jr B, McCashland T . Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant. 2002; 2(8):774-9. DOI: 10.1034/j.1600-6143.2002.20812.x. View

Dumortier J, Czyglik O, Poncet G, Blanchet M, Boucaud C, Henry L . Eversion thrombectomy for portal vein thrombosis during liver transplantation. Am J Transplant. 2002; 2(10):934-8. DOI: 10.1034/j.1600-6143.2002.21009.x. View

Heimbach J, Gores G, Haddock M, Alberts S, Nyberg S, Ishitani M . Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004; 24(2):201-7. DOI: 10.1055/s-2004-828896. View

Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B . Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005; 54(5):691-7. PMC: 1774501. DOI: 10.1136/gut.2004.042796. View

10.

Xia V, Taniguchi M, Steadman R . The changing face of patients presenting for liver transplantation. Curr Opin Organ Transplant. 2008; 13(3):280-4. DOI: 10.1097/MOT.0b013e328300a070. View

11.

Mazzaferro V, Llovet J, Miceli R, Bhoori S, Schiavo M, Mariani L . Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2008; 10(1):35-43. DOI: 10.1016/S1470-2045(08)70284-5. View

12.

Englesbe M, Kubus J, Muhammad W, Sonnenday C, Welling T, Punch J . Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl. 2009; 16(1):83-90. DOI: 10.1002/lt.21941. View

13.

Weismuller T, Fikatas P, Schmidt J, Barreiros A, Otto G, Beckebaum S . Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept. Transpl Int. 2010; 24(1):91-9. DOI: 10.1111/j.1432-2277.2010.01161.x. View

14.

Ravaioli M, Zanello M, Grazi G, Ercolani G, Cescon M, Del Gaudio M . Portal vein thrombosis and liver transplantation: evolution during 10 years of experience at the University of Bologna. Ann Surg. 2010; 253(2):378-84. DOI: 10.1097/SLA.0b013e318206818b. View

15.

Schlitt H, Loss M, Scherer M, Becker T, Jauch K, Nashan B . [Current developments in liver transplantation in Germany: MELD-based organ allocation and incentives for transplant centres]. Z Gastroenterol. 2011; 49(1):30-8. DOI: 10.1055/s-0029-1245946. View

16.

Sapisochin G, Fidelman N, Roberts J, Yao F . Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl. 2011; 17(8):934-42. DOI: 10.1002/lt.22307. View

17.

Murad S, Kim W, Therneau T, Gores G, Rosen C, Martenson J . Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology. 2012; 56(3):972-81. PMC: 3830980. DOI: 10.1002/hep.25629. View

18.

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

19.

Francoz C, Valla D, Durand F . Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol. 2012; 57(1):203-12. DOI: 10.1016/j.jhep.2011.12.034. View

20.

Murad S, Kim W, Harnois D, Douglas D, Burton J, Kulik L . Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012; 143(1):88-98.e3. PMC: 3846443. DOI: 10.1053/j.gastro.2012.04.008. View